Literature DB >> 10866493

Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone.

P Tassone, S Forciniti, E Galea, R Savino, M C Turco, P Iacopino, P Tagliaferri, G Morrone, G Ciliberto, S Venuta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10866493     DOI： 10.1038/sj.cdd.4400635

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN： 1350-9047            Impact factor:   15.828


× No keyword cloud information.
  9 in total

Review 1.  New frontiers in the treatment of multiple myeloma.

Authors:  Janice Jin Hwang; Irene M Ghobrial; Kenneth C Anderson
Journal:  ScientificWorldJournal       Date:  2006-12-06

2.  Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Authors:  Emanuela Leone; Eugenio Morelli; Maria T Di Martino; Nicola Amodio; Umberto Foresta; Annamaria Gullà; Marco Rossi; Antonino Neri; Antonio Giordano; Nikhil C Munshi; Kenneth C Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

3.  Interleukin-6 receptor superantagonist Sant7 inhibits TGF-beta-induced proliferation of human lung fibroblasts.

Authors:  L Gallelli; D Falcone; G Pelaia; T Renda; R Terracciano; N Malara; A Vatrella; A Sanduzzi; B D'Agostino; F Rossi; C Vancheri; R Maselli; S A Marsico; R Savino
Journal:  Cell Prolif       Date:  2008-04-24       Impact factor: 6.831

Review 4.  Apoptotic signaling in multiple myeloma: therapeutic implications.

Authors:  Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2003-08       Impact factor: 2.490

Review 5.  Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.

Authors:  P Tassone; P Neri; R Burger; M T Di Martino; E Leone; N Amodio; M Caraglia; P Tagliaferri
Journal:  Curr Cancer Drug Targets       Date:  2012-09       Impact factor: 3.428

6.  Antibody-based therapies in multiple myeloma.

Authors:  Yu-Tzu Tai; Kenneth C Anderson
Journal:  Bone Marrow Res       Date:  2011-03-02

Review 7.  miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.

Authors:  Nicola Amodio; Marco Rossi; Lavinia Raimondi; Maria Rita Pitari; Cirino Botta; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2015-05-30

Review 8.  Mouse models of multiple myeloma: technologic platforms and perspectives.

Authors:  Marco Rossi; Cirino Botta; Mariamena Arbitrio; Rosa Daniela Grembiale; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Oncotarget       Date:  2018-04-13

Review 9.  Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma.

Authors:  Jianbiao Zhou; Wee-Joo Chng
Journal:  Cells       Date:  2022-03-10       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.